Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pembrolizumab
94%
Selinexor
41%
Immune Checkpoint Inhibitors
39%
Stable Disease
37%
Tumor
37%
MD Anderson Cancer Center
35%
Advanced Solid Tumors
31%
Partial Response
28%
In Cancer
27%
Immune Cells
25%
Basket Trial
25%
Phase II Clinical Trial
25%
Treatment Outcome
25%
Rare Cancer
24%
Center Experience
23%
Phase Ib Study
23%
Clinical Trials
22%
Objective Response Rate
21%
Rare Tumors
21%
Programmed Death-ligand 1 (PD-L1)
20%
Adverse Events
20%
Multi-arm
19%
Single Center
19%
Carboplatin
18%
Basic Immunology
17%
Response-outcome
17%
Paclitaxel
17%
Clinical Benefit Rate
17%
Immune-related Adverse Events
17%
Immune Response
16%
Overall Survival
16%
Solid Tumors
16%
Confidence Interval
16%
Non-progression
16%
Treatment-related Adverse Events
15%
Progression-free Survival
14%
Translational Relevance
14%
Predictive Biomarker
14%
Tumor Microenvironment
14%
Complete Response
14%
Cancer Patients
14%
Progression Rate
14%
Clinical Benefit
13%
Tolerability
13%
Immune-related
13%
Targeted Agents
12%
Improved Outcomes
12%
T Cells
12%
Tumor-infiltrating Lymphocytes
12%
Disease Control Rate
12%
Medicine and Dentistry
Pembrolizumab
100%
Cancer
56%
Clinical Trial
54%
Diseases
47%
Malignant Neoplasm
45%
Neoplasm
44%
Immune Checkpoint Inhibitor
31%
Immunotherapy
31%
Adverse Event
30%
Rare Tumor
22%
Progression Free Survival
21%
Overall Survival
20%
Uterine Cancer
14%
Solid Malignant Neoplasm
14%
Adrenal Cortex Carcinoma
14%
Biopsy Technique
14%
Squamous Cell Carcinoma
14%
Monotherapy
13%
Selinexor
11%
Systematic Review
11%
Utomilumab
11%
Oncology
11%
Response Evaluation Criteria in Solid Tumors
10%
Programmed Death-Ligand 1
10%
Mammalian Target of Rapamycin Inhibitor
10%
Hazard Ratio
9%
Immunity
9%
Diarrhea
9%
Programmed Cell Death
9%
Cancer of Unknown Primary Origin
8%
Pheochromocytoma
8%
Paraganglioma
8%
Somatomedin C Receptor
8%
Systemic Therapy
8%
Next Generation Sequencing
8%
Radiation Therapy
8%
Targeted Therapy
8%
Progressive Disease
8%
Exanthem
7%
Combination Therapy
7%
Comprehensive Genomic Profiling
7%
Epidermal Growth Factor Receptor
7%
Clear Cell Renal Cell Carcinoma
6%
Advanced Cancer
6%
Tumor Infiltrating Lymphocyte
6%
Tumor Progression
6%
Cancer Therapy
6%
Biological Marker
6%
Nivolumab
6%
Antineoplastic Activity
6%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
83%
Diseases
66%
Malignant Neoplasm
58%
Neoplasm
52%
Clinical Trial
51%
Solid Malignant Neoplasm
50%
Selinexor
41%
Adverse Event
36%
Immunotherapy
24%
Progression Free Survival
22%
Immune Checkpoint Inhibitor
22%
Overall Survival
21%
Carboplatin
18%
Paclitaxel
17%
Advanced Cancer
14%
Monotherapy
13%
Epidermal Growth Factor Receptor
13%
Somatomedin C Receptor
11%
Adrenal Cortex Carcinoma
11%
Combination Therapy
10%
Endometrium Cancer
10%
Non Small Cell Lung Cancer
10%
Thrombocytopenia
9%
Vasculotropin
8%
Tolerability
8%
Remission
8%
Anemia
8%
Ovary Cancer
8%
Preclinical Study
8%
Breast Cancer
8%
Diarrhea
8%
Connective Tissue Cancer
7%
Mammalian Target of Rapamycin Inhibitor
7%
Antitumor Activity
7%
Uvea Melanoma
7%
Neutropenia
6%
Renal Cell Carcinoma
6%
Chemotherapy
6%
Lung Cancer
6%
Nivolumab
6%
Anticancer Drug
5%
Spartalizumab
5%
Skin Carcinoma
5%
Pazopanib
5%
Cytotoxic Agent
5%
Cancer of Unknown Primary Site
5%
Placebo
5%
Granulosa Cell Tumour
5%
Everolimus
5%
Randomized Clinical Trial
5%